These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 34286440)
1. CXCL11 Signaling in the Tumor Microenvironment. Gao Q; Zhang Y Adv Exp Med Biol; 2021; 1302():41-50. PubMed ID: 34286440 [TBL] [Abstract][Full Text] [Related]
2. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4 Hart M; Nickl L; Walch-Rueckheim B; Krammes L; Rheinheimer S; Diener C; Taenzer T; Kehl T; Sester M; Lenhof HP; Keller A; Meese E J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229509 [TBL] [Abstract][Full Text] [Related]
3. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. Karin N Front Immunol; 2020; 11():976. PubMed ID: 32547545 [TBL] [Abstract][Full Text] [Related]
5. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. Hensbergen PJ; Wijnands PG; Schreurs MW; Scheper RJ; Willemze R; Tensen CP J Immunother; 2005; 28(4):343-51. PubMed ID: 16000952 [TBL] [Abstract][Full Text] [Related]
6. Upregulation of angiostatic chemokines IP-10/CXCL10 and I-TAC/CXCL11 in human obesity and their implication for adipose tissue angiogenesis. Hueso L; Ortega R; Selles F; Wu-Xiong NY; Ortega J; Civera M; Ascaso JF; Sanz MJ; Real JT; Piqueras L Int J Obes (Lond); 2018 Aug; 42(8):1406-1417. PubMed ID: 29795466 [TBL] [Abstract][Full Text] [Related]
7. Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts. Lau TS; Chung TK; Cheung TH; Chan LK; Cheung LW; Yim SF; Siu NS; Lo KW; Yu MM; Kulbe H; Balkwill FR; Kwong J J Pathol; 2014 Jan; 232(1):43-56. PubMed ID: 24014111 [TBL] [Abstract][Full Text] [Related]
8. CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7. Puchert M; Obst J; Koch C; Zieger K; Engele J Cytokine; 2020 Jan; 125():154809. PubMed ID: 31437604 [TBL] [Abstract][Full Text] [Related]
9. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Tokunaga R; Zhang W; Naseem M; Puccini A; Berger MD; Soni S; McSkane M; Baba H; Lenz HJ Cancer Treat Rev; 2018 Feb; 63():40-47. PubMed ID: 29207310 [TBL] [Abstract][Full Text] [Related]
10. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Proost P; Mortier A; Loos T; Vandercappellen J; Gouwy M; Ronsse I; Schutyser E; Put W; Parmentier M; Struyf S; Van Damme J Blood; 2007 Jul; 110(1):37-44. PubMed ID: 17363734 [TBL] [Abstract][Full Text] [Related]
11. The role of CXCR3 and its ligands CXCL10 and CXCL11 in the pathogenesis of celiac disease. Haghbin M; Rostami-Nejad M; Forouzesh F; Sadeghi A; Rostami K; Aghamohammadi E; Asadzadeh-Aghdaei H; Masotti A; Zali MR Medicine (Baltimore); 2019 Jun; 98(25):e15949. PubMed ID: 31232926 [TBL] [Abstract][Full Text] [Related]
12. CXCL12 Signaling in the Tumor Microenvironment. Portella L; Bello AM; Scala S Adv Exp Med Biol; 2021; 1302():51-70. PubMed ID: 34286441 [TBL] [Abstract][Full Text] [Related]
13. CXCL11 promotes self-renewal and tumorigenicity of α2δ1 Zhang Y; Zhao W; Li S; Lv M; Yang X; Li M; Zhang Z Cancer Lett; 2019 May; 449():163-171. PubMed ID: 30771435 [TBL] [Abstract][Full Text] [Related]
14. Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach. Costantini S; Raucci R; De Vero T; Castello G; Colonna G Cytokine; 2013 Oct; 64(1):316-21. PubMed ID: 23773308 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis. Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110 [TBL] [Abstract][Full Text] [Related]
17. Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. Rupertus K; Sinistra J; Scheuer C; Nickels RM; Schilling MK; Menger MD; Kollmar O Clin Exp Metastasis; 2014 Apr; 31(4):447-59. PubMed ID: 24493023 [TBL] [Abstract][Full Text] [Related]
18. Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis. Li Q; Sun J; Cao Y; Liu B; Li L; Mohammadtursun N; Zhang H; Dong J; Wu J Biomed Pharmacother; 2020 Mar; 123():109735. PubMed ID: 31864210 [TBL] [Abstract][Full Text] [Related]
19. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Nedjai B; Li H; Stroke IL; Wise EL; Webb ML; Merritt JR; Henderson I; Klon AE; Cole AG; Horuk R; Vaidehi N; Pease JE Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630 [TBL] [Abstract][Full Text] [Related]
20. Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity. Moreno B; Hueso L; Ortega R; Benito E; Martínez-Hervas S; Peiro M; Civera M; Sanz MJ; Piqueras L; Real JT Microvasc Res; 2022 Jan; 139():104254. PubMed ID: 34534571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]